Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT03545256

Sentinel. Ambulatory. Oral Cavity. Oropharynx (S.A.C.O)

Led by University Hospital, Montpellier · Updated on 2025-09-30

25

Participants Needed

1

Research Sites

421 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a single-center pilot study of open-label, non-randomized interventional research based on the outpatient management of 30 patients with T1-N0 or T2-N0 cancer in the oral cavity or oropharynx.

CONDITIONS

Official Title

Sentinel. Ambulatory. Oral Cavity. Oropharynx (S.A.C.O)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female 18 years old or older
  • Affiliated with a social security system or beneficiary of such a system
  • Provided informed consent and received patient information
  • Not currently participating in another clinical trial
  • Diagnosed with primary squamous cell carcinoma of the oral cavity or oropharynx confirmed by biopsy within 1 month
  • Tumor operable based on TNM stage, location, and patient general condition
  • Underwent Oto-Rhino-Laryngology panendoscopy to exclude a second tumor and determine tumor stage
  • Tumor staged as T1 or T2, N0, M0
  • Surgery and sentinel lymph node technique proposed by multidisciplinary meeting
  • Eligible for ambulatory surgery
  • Meets anesthetic criteria for outpatient hospitalization including stable ASA I, II, or III score
  • Able to understand the study purpose and procedures
Not Eligible

You will not qualify if you...

  • Missing any inclusion criteria
  • Currently treated for another cancer
  • Tumor is non-infiltrating such as high grade dysplasia or carcinoma in situ
  • Incomplete tumor excision with invaded margins without additional healthy tissue removal
  • Contraindication to sentinel lymph node surgery or lymph node dissection
  • Contraindication to radiotherapy
  • Allergy or intolerance to injected tracer, especially Technetium-99
  • Pregnancy
  • Refusal to accept all treatments including nodal diagnosis, lymph node dissection if needed, or follow-up
  • Unable to be followed for 2 years
  • Refusal to accept study monitoring or provide necessary information
  • Previously treated for this tumor other than biopsy
  • Received chemotherapy or immunotherapy for other cancers in head and neck area within last 6 months
  • History of cervical or head and neck radiotherapy
  • Previous cervical surgery
  • Legally protected patients under guardianship
  • Patients deprived of liberty by administrative decision
  • Pregnant or lactating women per legal regulations

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Gui de Chauliac Hospital, ENT Department 80 rue Augustin Fliche

Montpellier, Hérault, France, 34295

Actively Recruiting

Loading map...

Research Team

R

Renaud GARREL, ENT

CONTACT

C

César CARTIER, ENT

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here